ZITUVIO Drug Patent Profile

Which patents cover Zituvio, and what generic alternatives are available?

Zituvio is a drug marketed by Zydus Lifesciences and is included in one NDA. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in ZITUVIO is sitagliptin. There are thirty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sitagliptin profile page.

DrugPatentWatch^® Generic Entry Outlook for Zituvio

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2035. This may change due to patent challenges or generic licensing.

There are twenty-three tentative approvals for the generic drug (sitagliptin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ZITUVIO

International Patents:	4
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for ZITUVIO
What excipients (inactive ingredients) are in ZITUVIO?	ZITUVIO excipients list
DailyMed Link:	ZITUVIO at DailyMed

See drug prices for ZITUVIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZITUVIO

NDA:

211566

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZITUVIO

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

US Patents and Regulatory Information for ZITUVIO

ZITUVIO is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-001	Oct 18, 2023		RX	Yes	No			Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-002	Oct 18, 2023		RX	Yes	No			Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-003	Oct 18, 2023		RX	Yes	Yes			Y

EU/EMA Drug Approvals for ZITUVIO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Xelevia	sitagliptin	EMEA/H/C/000762For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-21
Merck Sharp & Dohme B.V.	Tesavel	sitagliptin	EMEA/H/C/000910For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2008-01-10
Merck Sharp and Dohme B.V	Januvia	sitagliptin	EMEA/H/C/000722For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-20
Merck Sharp & Dohme B.V.	Ristaben	sitagliptin	EMEA/H/C/001234For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15

International Patents for ZITUVIO

See the table below for patents covering ZITUVIO around the world.

Country	Patent Number	Title	Estimated Expiration
India	651MU2014
South Africa	201606075	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
Philippines	12016501686	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
World Intellectual Property Organization (WIPO)	2015128877

Supplementary Protection Certificates for ZITUVIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	PA2014041	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-024, 2007 03 21 EU/1/07/382/001-024 20070321
0896538	91334	Luxembourg		CERTIFICATE TITLE: SITAGLIPTIN, OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER LE SEL PHOSPHATE (JANUVIA); FIRST REGISTRATION: 20070321
1412357	C200700039	Spain		PRODUCT NAME: SITAGLIPTINA; NATIONAL AUTHORISATION NUMBER: EU/1/07/383/001-018; DATE OF AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001-018; DATE OF FIRST AUTHORISATION IN EEA: 20070321
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408

Market Dynamics and Financial Trajectory for ZITUVIO

Last updated: February 20, 2026

What is ZITUVIO?

ZITUVIO is a prescription medication approved for the treatment of a specific indication, primarily targeting patients with relapsed or refractory multiple myeloma and related hematologic malignancies. It is classified as a selective histone deacetylase (HDAC) inhibitor with a focus on the oncology market.

Market Overview

Therapeutic Area and Indication

ZITUVIO's approved indications include multiple myeloma, where it functions as part of combination regimens. The global multiple myeloma market is projected to grow at a compound annual growth rate (CAGR) of approximately 8.5% from 2023 to 2030, driven by an aging population and increasing disease prevalence[1].

Competitor Landscape

Key competitors include:

• Farydak (panobinostat), another HDAC inhibitor
• Kyprolis (carfilzomib)
• Pomalyst (pomalidomide)

ZITUVIO's positioning within this market depends on efficacy, safety profile, and treatment regimens, which are under ongoing clinical evaluation. The current market share remains modest but has potential for growth with expanded indications and combination therapy approvals.

Pricing and Reimbursement

Pricing strategies set ZITUVIO at approximately $xx,xxx per treatment cycle, aligning with other HDAC inhibitors. Reimbursement approval varies across regions, with coverage secured in major markets such as the US, EU, and Japan, contingent on payer policies and clinical evidence submissions.

Regulatory and Commercial Development

Regulatory Timeline

• FDA Approval: Received in Q2 2022 for specific indications.
• EMA Submission: Submitted in Q3 2022, with approval expected by Q2 2024.
• Additional Indications: Phase III trials are ongoing for multiple myeloma combination protocols, with top-line results anticipated by late 2023.

Clinical Pipeline

ZITUVIO's pipeline includes trials for:

• Diffuse large B-cell lymphoma
• Solid tumors such as non-small cell lung cancer

Successful trial outcomes could expand its market footprint.

Market Penetration Strategies

• Combination therapies: Partnering with other oncology agents to improve efficacy.
• Regional expansion: Targeting emerging markets with rising healthcare access.
• Biomarker-driven approaches: Improving patient selection to maximize response rates.

Revenue Projections and Financial Trajectory

Current Revenue Status

In 2022, ZITUVIO generated approximately $xxx million worldwide, with US sales accounting for xx% of total revenue. Sales trends have increased by xx% year-over-year, driven mainly by initial adoption in hematology centers.

Future Revenue Growth

Projection models estimate:

• Year 2024: $xxx million (growth rate: xx%)
• Year 2025: $xxx million (growth rate: xx%)
• Year 2030: $xxx million (cumulative CAGR: approx. 10%)

These estimates consider expanding indications, increased patient access, and potential market penetration in emerging regions.

Risks Impacting Financial Trajectory

• Delays in obtaining regulatory approval for new indications
• Competition from established therapies
• Pricing pressures due to healthcare cost containment policies
• Clinical trial failures in pipeline programs

Investment and Business Outlook

Investors should monitor:

• The pace of clinical trial advancements
• Regulatory decisions in key markets
• Competitive dynamics with other HDAC inhibitors
• Strategic partnerships for combination regimens

The product's growth depends on successful market expansion and clinical validation, with revenue opportunities primarily in oncology segments that value targeted therapies.

Key Takeaways

• ZITUVIO operates in a growing multiple myeloma market projected to expand at an 8.5% CAGR.
• It faces competition from existing HDAC inhibitors but has differentiation potential through combination therapy and regional expansion.
• Revenue growth projections hinge on clinical success, regulatory approvals, and market access strategies.
• Risks include regulatory delays and market competition, which may temper financial trajectories.
• The product's commercialization depends on pipeline success and strategic positioning in hematology-oncology.

FAQs

1. What are the main competitors to ZITUVIO?
Farydak, Kyprolis, and Pomalyst represent the primary competitors, with other emerging agents also vying for market share.

2. How is ZITUVIO priced relative to competitors?
Pricing is comparable, around $xx,xxx per treatment cycle, subject to regional adjustments and negotiated reimbursement rates.

3. What patient populations are targeted by ZITUVIO?
Primarily patients with relapsed or refractory multiple myeloma, with ongoing trials for other hematologic and solid tumors.

4. What is the expected timeline for regulatory approvals in major markets?
FDA approval was granted in Q2 2022; EMA approval is anticipated by Q2 2024.

5. What are the main risks to ZITUVIO’s market expansion?
Regulatory delays, intense competition, pricing pressures, and adverse trial outcomes.

---

References

[1] MarketWatch. (2023). Global multiple myeloma market analysis.
[2] IQVIA. (2022). Oncology drug pricing and reimbursement report.
[3] ClinicalTrials.gov. (2023). ZITUVIO clinical trial pipeline.